跳至主要内容
临床试验/NCT01573052
NCT01573052已完成4 期

Comparison of Chlordiazepoxide and Gabapentin for Outpatient Alcohol Detoxification Treatment

VA Salt Lake City Health Care System1 个研究点 分布在 1 个国家目标入组 26 人开始时间: 2004年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
26
试验地点
1
主要终点
Epworth Sleepiness Scale (ESS)

研究概览

简要总结

A randomized, double-blind controlled trial comparing treatment outcomes between chlordiazepoxide, or gabapentin to treat alcohol withdrawal syndrome in alcohol dependent veteran subjects. The objective of this trial is to compare the safety and effectiveness of these two medications. Intervention is a fixed dose taper of chlordiazepoxide, or gabapentin over 6 days. Subjects will be evaluated for 7-10 days to monitor alcohol abstinence, withdrawal severity scores, adverse events including ataxia, sedation, cognitive function and alcohol craving.

详细描述

Chlordiazepoxide 25 mg and matching placebo capsules or gabapentin 300 mg and matching placebo capsules were were used. The chlordiazepoxide/placebo and gabapentin/placebo capsules were not identical in appearance. Study medications were packaged into a 7-day medication organizer. The dosing for each subject was either gabapentin 1200mg or chlordiazepoxide 100 mg orally days 1-3, gabapentin 900 mg or chlordiazepoxide 75 mg day 4, gabapentin 600 mg or chlordiazepoxide 50 mg day 5, and gabapentin 300 mg or chlordiazepoxide 25 mg day 6.

Adherence was assessed by pill counts and serum samples were obtained for study drug analysis. Serum samples were batched and sent to a contract laboratory so that study clinicians were blinded to the results until after the trial was completed. Presence of the assigned study medication in the blood served as a surrogate adherence marker.

Subjects also received prescriptions for daily oral therapeutic multiple vitamin tablets, folic acid 1 mg, and thiamine 100 mg.

A psychiatric history and physical examination, breath alcohol concentration, vital signs, CIWA-Ar (alcohol withdrawal scale), and blood chemistry including transaminases and complete blood cell count were obtained for baseline for all participants. Subjects were seen on weekdays for clinic follow-up appointments. Assessments performed at each study visit included CIWA-Ar, ESS (Epworth Sleepiness Scale), PACS (Penn Alcohol Craving Scale), and a brief examination to document mental status and assess coordination, which included assessment of stance, tandem gait, Romberg test, pronator drift, toe and heel walk, rapid-alternating-movements, and point-to-point movements. Breath alcohol concentration (BAC) was also measured (AlcoSensor, Intoximeters, Inc.) at each visit.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Alcohol dependent at risk for withdrawal symptoms

排除标准

  • Benzodiazepine dependent

研究组 & 干预措施

Chlordiazepoxide

Active Comparator

Chlordiazepoxide 25mg capsule or matching placebo capsule

干预措施: Chlordiazepoxide (Drug)

Gabapentin

Experimental

Gabapentin 300mg capsule or matching placebo capsule

干预措施: Gabapentin (Drug)

结局指标

主要结局

Epworth Sleepiness Scale (ESS)

时间窗: 1 week

ESS is an 8 item-scale and scores range between 0 and 24. The higher the score implies more daytime sleepiness.

PENN Alcohol Craving Scale

时间窗: 1 week

PENN is a 5 item self-rated scale of alcohol craving. Scores range from 0 (little craving for alcohol) to 30 (irresistable urge to drink alcohol)

次要结局

  • Clinical Institute Withdrawal Assessment-Alcohol (Revised)(CIWA-Ar)(1 week)

研究者

发起方
VA Salt Lake City Health Care System
申办方类型
Fed
责任方
Principal Investigator
主要研究者

Christopher J. Stock, PharmD

Investigational pharmacist

VA Salt Lake City Health Care System

研究点 (1)

Loading locations...

相似试验